Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?

Urology

Volumn 55, Issue 3, 2000, Pages 391-395

  Sarosdy, M F ^a   Schellhammer, P F ^b   Johnson, R ^c   Carroll, K ^c   Kolvenbag, G J C M ^c  

^a South Texas Urology and Urologic Oncology   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REGRESSION ANALYSIS; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FLUTAMIDE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0033982430     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00574-9     Document Type: Article

References (30)

1. Belanger A., Brochu M., Cliche J. Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer. J Clin Endocrinol Metab. 62:1986;812-815.
2. Bracci U., Di Silverio F. Role of cyproterone acetate in urology. Martin L., Motta M. Androgens and Antiandrogens. 1977;333-339 Raven Press, New York.
3. Labrie F., Dupont A., Belanger A., et al. New hormonal therapy in prostate cancer combined use of a pure antiandrogen and an LHRH agonist . Horm Res. 18:1983;18-27.
4. Labrie F., Dupont A., Belanger A., et al. Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc Natl Acad Sci U S A. 81:1984;3861-3863.
5. Labrie F., Dupont A., Belanger A., et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer a marked improvement in response and survival . J Steroid Biochem. 23:1985;833-841.
6. Crawford E.D., Eisenberger M., McLeod D., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 321:1989;419-424.
7. Tyrrell C.J., Altwein J., Klippe L.F., et al. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. J Urol. 146:1991;1321-1326.
8. Boccardo F., Pace M., Rubagotti A., et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. Eur J Cancer. 29A:1993;1088-1093.
9. Di Silverio F., Serio M., D'Eramo G., et al. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer a multicenter Italian study . Eur Urol. 18:(suppl 3):1990;54-61.
10. Denis L.J., Keuppens F., Smith P., et al. Maximal androgen blockade final analysis of EORTC phase III trial 30853 . Eur Urol. 33:1998;144-151.
11. de Voogt H.J., Studer U., Schröder F., et al. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. Eur Urol. 33:1998;152-158.
12. Iversen P., Christensen M., Friis E., et al. A phase III trial of Zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer. 66:(5 suppl):1990;1058-1066.
13. Eisenberger M.A., Blumenstein B., Crawford E., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 339:1998;1036-1042.
14. Dijkman G.A., Janknegt R., de Reijke T., et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. J Urol. 158:1997;160-163.
15. Robinson M.R. A further analysis of European Organization for Research and Treatment of Cancer protocol 30805. Orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose diethylstilbestrol. Cancer. 72:(suppl 12):1993;3855-3857.
16. Zalcberg J.R., Raghaven D., Marshall V., et al. Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate - an Australian multicentre trial. Br J Urol. 77:1996;865-869.
17. Beland G., Elhiali M., Fradet Y., et al. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer. 66:(5 suppl):1990;1074-1079.
18. Namer M., Toubol J., Caty A., et al. A randomized, double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer. J Steroid Biochem Mol Biol. 37:1990;909-915.
19. Bennett C., Tosteson T., Schmitt B., et al. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide . Prostate Cancer Prostatic Dis. 2:1999;4-8.
20. Maximum androgen blockade in advanced prostate cancer an overview of 22 randomised trials with 3283 deaths in 5710 patients . Lancet. 346:1995;265-269.
21. Kaisary A., Tyrrell C., Peeling W., et al. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 67:1991;502-508.
22. Vogelzang N., Chodak G., Soloway M., et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer final results of a randomized trial . Urology. 46:1995;220-226.
23. Schellhammer P.F., Sharifi R., Block N.L., et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma final report of a double-blind, randomized, multicenter trial . Urology. 50:1997;330-336.
24. Schellhammer P., Sharifi R., Block N., et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology. 45:1995;745-752.
25. Labrie F., Dupont A., Belanger A., et al. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol. 138:1987;804-806.
26. Jacobi G., Wenderoth U., Ehrenthal W., et al. Endocrine and clinical evaluation of 107 patients with advanced prostate carcinoma under long-term pernasal buserelin or intramuscular decapeptyl depot treatment. Am J Clin Oncol. 11:(suppl 1):1988;S36-S43.
27. Kuhn J.M., Billebaud T., Navratil H., et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med. 321:1989;413-418.
28. Mahler C. Is disease flare a problem? Cancer. 72:(suppl 12):1993;3799-3802.
29. Thompson I., Zeidman E., Rodriguez F. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol. 144:1990;1479-1480.
30. Peeling W. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in the treatment of prostate cancer. Urology. 33:(suppl 5):1989;45-52.